Posted on

Cbd oil for eating disorders

Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa

No studies of cannabidiol (CBD) have focused on Anorexia Nervosa (AN). Dose, side effects, tolerability, acceptability of pure CBD in AN must be established. The current study is an important first step in the investigation of CBD for AN. Cannabis products have been recently legalized in many states, and CBD in particular has been shown to reduce anxiety. Therefore, CBD may represent a promising new treatment for AN. The endocannabinoid system is involved in the regulation of functions relevant to eating disorders. Furthermore, data suggest that eating disorders are associated with alterations of the endocannabinoid system. Prior attempts to target the endocannabinoid system in AN have focused on CB1 receptor agonists that can increase anxiety. Moreover, CBD may be particularly beneficial in decreasing anxiety in AN via its action at serotonin receptors. Lastly, the impact of CBD on eating behavior and weight in AN must be determined. The current study seeks to explore these hypotheses using the aims in the following section.

Condition or disease Intervention/treatment Phase
Anorexia Nervosa Drug: Cannabidiol Drug: Placebo Early Phase 1

Layout table for study information

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Placebo-controlled, randomized, double-blind study
Masking: Double (Participant, Investigator)
Masking Description: The PI and research coordinator administering the medication will be blinded to the randomization schedule. The research subject will be blinded to what medication she receives.
Primary Purpose: Treatment
Official Title: The Role of Cannabidiol in Regulating Meal Time Anxiety in Anorexia Nervous: Safety, Tolerability and Pharmacokinetics
Actual Study Start Date : January 20, 2022
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : May 2023

Days 1 to 7: Patients will receive CBD 2.5 mg/kg in divided doses BID for 7 days. Days 8 to 14: Patients will receive an increase dose of 7.5 mg/kg of CBD in divided doses.

Days 15 to 21: Patients will receive an increased dose of 12.5 mg/kg CBD, in divided doses. If patients experience dose limiting side-effects, they ill be maintained on the lowest tolerated dose.

Days 1 to 7: Patients will receive placebo in divided doses BID for 7 days. Days 8 to 14: Patients will continue to receive placebo in divided doses. Days 15 to 21: Patients will receive continue to receive placebo in divided doses.

    Committee of Clinical Investigations UKU-Side Effect Scale Week 1 [ Time Frame: After completion of Week 1 of treatment ]

The Committee of Clinical Investigations (UKU) scale is used to rate psychiatric (e.g., depression, failing memory, concentration difficulty), neurological (e.g., rigidity, tremor, epileptic seizure), and autonomic (e.g., nausea, diarrhea, tachycardia) side effects, plus others. Higher scores indicate more side effects.

The Committee of Clinical Investigations (UKU) scale is used to rate psychiatric (e.g., depression, failing memory, concentration difficulty), neurological (e.g., rigidity, tremor, epileptic seizure), and autonomic (e.g., nausea, diarrhea, tachycardia) side effects, plus others. Higher scores indicate more side effects.

The Committee of Clinical Investigations (UKU) scale is used to rate psychiatric (e.g., depression, failing memory, concentration difficulty), neurological (e.g., rigidity, tremor, epileptic seizure), and autonomic (e.g., nausea, diarrhea, tachycardia) side effects, plus others. Higher scores indicate more side effects.

Blood levels for CBD, 6-OH-CBD, 7COOH-CBD, THC. The results will be compared to standard laboratory values.

Blood levels for CBD, 6-OH-CBD, 7COOH-CBD, THC. The results will be compared to standard laboratory values.

Blood levels for CBD, 6-OH-CBD, 7COOH-CBD, THC. The results will be compared to standard laboratory values.

Assesses the change from baseline in BMI, Eating Restraint, Eating Concern, Shape Concern, Weight Concern over the course of treatment. Each of those subscales is rated between 0 and 5. Subscales are calculated based on the average scores for the respective subscale. Higher scores indicate poorer outcome.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study: 18 Years to 40 Years (Adult)
Sexes Eligible for Study: Female
Gender Based Eligibility: Yes
Gender Eligibility Description: Female individuals will be enrolled. Gender eligibility is based on biological sex of participants.
Accepts Healthy Volunteers: No
  1. Must currently meet DSM-5 criteria for AN-R and AN Spectrum Disorders (i.e., Atypical AN) based on the Structured Clinical Interview for the DSM-5 (SCID-5-RV)
  2. Have a duration of illness ≥ 6 months
  3. Be medically stable as assessed by a comprehensive medical and behavioral evaluation conducted by a study physician
  1. Psychotic illness/other mental illness requiring inpatient hospitalization
  2. Current dependence on drugs or alcohol
  3. Physical conditions (e.g., diabetes mellitus, pregnancy) known to influence eating or weight or liver disease which may affect pharmacokinetics of the study drug
  4. Use of other psychoactive medications
  5. Significant changes in medication in past month
  6. Expression of acute suicidality
  7. Previous hypersensitivity reaction to Epidiolex or any of its constituents
See also  Max dosage of cbd oil for 8 year old

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04878627

Cannabis for Eating Disorders

Can medical marijuana help people with eating disorders like anorexia and bulimia? Cannabis is often used to increase appetite in people suffering from conditions such as cancer or AIDS/HIV. The idea of using cannabis for those with eating disorders is not exactly new, and in many ways the logic is entirely sound. However, eating disorders have several key differences to wasting developing from other chronic illnesses, meaning that treating them requires slightly different approaches.

Using cannabis for eating disorders is a subject we have written about before here at Leafwell. Today we’ll learn all about the potential of cannabis as a medication for a variety of eating disorders.

What is an eating disorder?

One of the key defining symptoms of an eating disorder is an unhealthy attitude towards food and eating either too much or too little. Other symptoms include an unhealthy obsession with weight and body shape, over-exercising, obsessive dieting, binge-eating (sometimes followed by intentional vomiting, or “purging”), extreme dissatisfaction with one’s own appearance (Body Dysmorphic Disorder, or BDD) depression, anxiety and extreme feelings of guilt, regret and/or worthlessness.

In some instances, an eating disorder may lead to “refeeding syndrome”, which is when malnourished or starved people take in food too quickly after a fasting period and develop electrolyte disorders. This leads to further pulmonary, cardiac, neuromuscular and blood complications. Refeeding syndrome can be potentially fatal. Other long-term complications include increased likelihood of stress fractures and Raynaud syndrome.

There are various types of eating disorders, including:

  • Anorexia nervosa – keeping your weight as low as possible by purposefully not eating enough food, exercising too much or both.
  • Binge eating disorder (BED) – losing control of your eating and eating too much at once, until you are uncomfortably full. Often followed by feelings of guilt and regret.
  • Bulimia – Binge eating in a small amount of time, then deliberately feeling sick, using laxatives or exercising too much in order to prevent weight gain.
  • Obesity – While not always considered an “eating disorder”, obesity does follow many of the same patterns as other eating disorders, including binge eating and an unhealthy relationship with food. Indeed, it is not unheard of for a person to swing between anorexia and obesity.
  • Other specified feeding or eating disorder (OSFED) – an eating disorder that doesn’t necessarily match all the symptoms of one of the above, and/or has “mixed” symptoms from one or more of the above. OSFED can include atypical anorexia, avoidant/restrictive food intake beyond that of “picky eating”, night eating syndrome, anorexia athletica and eating disorders related to type-I diabetes (e.g. deliberate insulin under use in order to prevent weight gain).
See also  Cbd hemp oil for horses reviews

Some statistics on Eating Disorders

Deaths from Eating disorders in 2012 per million persons. Statistics from WHO. Data from World Health Organization Estimated Deaths 2012 Vector map from BlankMap-World6, compact.svg by Canuckguy et al. Source

Eating disorders affect approximately 30 million people in the US. They have the highest mortality rate of any mental illness, and are often comorbid with mood disorders, anxiety disorders and substance misuse disorders (especially alcohol).

Eating disorders affect a wide variety of people. Women aged 50 or over, girls aged between 13 – 17 and women in high-pressured environments such as athletics are the highest risk groups for anorexia and bulimia. Restrictive eating is more likely to be found in boys and men. A 2015-2016 study by the Center for Disease Control and Prevention (CDC) showed that 39.6% of US adults age 20 and older were obese as of 2015-2016 (37.9% for men and 41.1% for women). Other risk factors include:

    to under- and overfeeding of the fetus during pregnancy. Maternal obesity and malnutrition play a huge role in the development of eating disorders among offspring.
  • Adiposity rebound – the “adiposity rebound” refers to the age when the second rise in body-mass index (BMI) occurs, which is between 3 – 7 years old. An early age adiposity rebound is correlated with obesity in later life.
  • Early life malnutrition and/or lack of breastfeeding – early nutrient deprivation can lead to a change in the body’s metabolism, leading to fat storage. This can make people vulnerable to obesity as adolescents and adults. Those who are not breastfed may suffer from stunted growth or grow too fast, leading to an earlier-onset adipose rebound. This is one reason why malnutrition, a lack of access to food and obesity are often linked and found together in impoverished parts of the world.
  • Steroid-based medications such as prednisone can lead to weight-gain.

What is Cachexia?

While cachexia (which means, “weakness and wasting of the body due to severe chronic illness”) is often associated with conditions such as anorexia, a person who is suffering from cachexia is not necessarily suffering from an eating disorder. Cachexia can be caused by many illnesses and conditions, as well as treatments and medications. Many of those with cachexia may well have a perfectly fine relationship with food, but are unfortunate enough to suffer from a condition that causes them to lose weight and muscle.

Anorexia Athletica

Those in highly competitive environments such as sports and athletics, where extreme fastidiousness is practiced with regards to diet and exercise, eating disorders are not uncommon. Many athletes also need a high intake of calories, meaning they need to learn portion control when training slows down or ceases. Athletes of all types can potentially suffer from eating disorders.

Even boxers and wrestlers, who are considered some of the strongest athletes in the world, often dehydrate, starve and over-exert themselves in order to make weight, which can lead to all sorts of health problems. Gymnasts, dancers, figure skaters, weightlifters, bodybuilders, synchronized swimmers, and endurance runners are other examples of athletes who may suffer from eating disorders due to the emphasis on weight and appearance.

How Does Cannabis Help Eating Disorders?

When it comes to using cannabis for conditions such as anorexia, people see the logic quite easily. However, when it comes to obesity (as well as diabetes), people find the concept of using cannabinoid-based medications to help treat it unusual. Yet, regular use of cannabis is actually linked to lower BMI, even when controlling for diet, exercise and alcohol consumption. While these studies do not prove for sure that cannabis use can help people maintain a healthy weight, there are several sound theories as to why cannabinoids may be used to help maintain a healthy appetite for both over- and under- eaters. These include:

See also  Cbd oil for anxiety in teenager

The endocannabinoid system (ECS) plays a role in regulating appetite. Cannabinoids such as tetrahydrocannabinol (THC) stimulate appetite and food intake.

Download Free Guide to the ECS
  • There is some suggestion that those who suffer from eating disorders have a disruption and/or dysregulation in the production of the hormones leptin (which can regulate energy balance by inhibiting hunger) and ghrelin (the “hunger hormone”, which stimulates appetite).
  • Cannabis use in HIV-infected men leads to an increase in plasma levels of ghrelin and leptin. THC in particular seems to have this effect.

Repeated exposure to THC may initially stimulate appetite, but use over the long-term could dampen CB1 receptor sensitivity, thus dampening hunger signals.

Some suggest that cannabis “supercharges” the body’s metabolism, meaning that fat is burnt off faster and levels of fasting insulin are lower. The body may be more sensitive to the effects of sugar while using cannabinoids, meaning that the brain sends signals to stop eating sooner than it usually would. So, while cannabis users may get the “munchies”, they may also have a tendency to stop eating sooner and only until they are full, rather than over-full.

There is much interest in the cannabinoid tetrahydrocannabivarin (THCV) for obesity and diabetes. THCV is a CB1 receptor antagonist, meaning that it has the opposite effect as THC when in low doses (THCV is a CB1 receptor agonist in high doses) and curbs hunger. In studies on mice, researchers found that THCV did not significantly affect food intake or body weight gain. THCV did, however, reduce glucose intolerance and improve insulin sensitivity. Such studies could offer hope to diabetics, but research on humans is necessary before making any assertions.

Cannabidiol (CBD) can also help control blood-sugar levels and reduce the production of fat while also reducing inflammation caused by insulin resistance.
Cannabis can potentially help with the depression and anxiety often associated with eating disorders. In turn, this may lead to an easier, less stressful relationship with food.

Are There Any Potential Negatives with Using Cannabinoids for Eating Disorders?

While cannabis can help improve the mood for many, for some using too much THC may lead to increased anxiety or paranoia. Also, if a person has been starving themselves for too long, care must be taken not to binge on food, lest refeeding syndrome occurs. Some may also be attracted to the idea that cannabis can help lose weight, which is beneficial for some but not necessarily others. Therefore, care must be taken to prevent misuse.

Those suffering from eating disorders such as anorexia or bulimia may be interested in low doses of THC and CBD, whereas those who are obese (or just plain overweight) may look into a combination of low doses of THC and THCV, combined with CBD. However, this is only theoretical, and has not been tested clinically. As there are few effective medications for eating disorders, cannabinoids represent an extremely promising avenue to look at as a potential therapeutic target.

There has been a look into other cannabis-based treatments for obesity in the past, namely Rimonabant. However, Rimonabant was not approved for usage due to its psychiatric side effects. Rimonabant has also been reported to cause partial seizures in those who suffer from epilepsy. It must also be noted that Rimonabant is a synthetic cannabinoid. We here at Leafwell have looked at the pros and cons of synthetic cannabinoids before, and as such we recommend being highly cautious of using them.

Remember: the endocannabinoid system is very powerful, and our efforts to replicate the safety margins of phytocannabinoids have generally not been successful so far. In short, the natural form of the cannabis plant is probably best for eating disorders and other conditions.

If you are suffering from an eating disorder and think you may be helped by cannabinoid-based medications, feel free to check out our medical card page and set up an appointment with one of our physicians.